The Weekender
NewLimit Secures $435M for Reversing Aging Scientific Research
Biotech startup NewLimit just secured a massive $435 million, aiming to launch its first aging reprogramming medicine into human clinical trials next year, as per its blog .
Evan Holloway·June 7, 2026
